Fetal growth and acute childhood leukemia: looking beyond birth weight

Elizabeth Milne1, Crystal L Laurvick, Eve Blair

  • 1Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia. lizm@ichr.uwa.edu.au

Insights

Accelerated fetal growth, not just high birth weight, increases the risk of childhood acute lymphoblastic leukemia (ALL). This finding suggests a potential role for insulin-like growth factor I in ALL development.

Area of Science:

  • Pediatric Oncology
  • Epidemiology
  • Perinatal Health

Background:

  • Childhood leukemia is a significant health concern.
  • Understanding risk factors for leukemia, such as birth characteristics, is crucial for prevention and early detection.

Purpose of the Study:

  • To investigate the association between birth weight, intrauterine growth, and the risk of childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Main Methods:

  • Population-based cohort study in Western Australia (1980-2004).
  • Followed 576,593 infants from birth to diagnosis, death, or end of follow-up (2005).
  • Analyzed data using Cox regression.

Main Results:

  • A positive association was found between the proportion of optimal birth weight and ALL risk, particularly in children under 5 years.
  • Accelerated fetal growth, indicated by optimal birth weight proportion, was linked to a ~40% increase in ALL risk in younger children.
  • Findings for AML were inconclusive due to small sample size.

Conclusions:

  • Accelerated fetal growth, rather than high birth weight itself, may play a role in the etiology of ALL.
  • Insulin-like growth factor I is a potential factor in the causal pathway of ALL.
  • Further research is needed to confirm findings for AML.

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...